Select Mergers & Acquisitions and Strategic Collaborations
Represented Tidal Therapeutics, Inc. as interim CBO in $470 million acquisition by Sanofi.
Represented Torque Therapeutics, Inc. in a merger with Cogen Therapeutics, Inc. and creation of a new company, Repertoire Immune Medicines, Inc.
Advised Voyager Therapeutics, Inc. on its research and license option agreement with Abbvie Inc. to develop vectorized Tau antibodies for treatment of Alzheimer’s disease and other tauopathies with $69 million upfront and up to $1.2 billion in milestones.
Advised Voyager Therapeutics, Inc. in connection with negotiation of restructuring of gene therapy collaboration with Sanofi where Voyager gains worldwide rights to the Huntington’s disease program and ex-U.S. rights to the Friedreich’s ataxia program, and Sanofi obtains exclusive option rights to select novel AAV capsids owned or controlled by Voyager for exclusive use for up to two non-central nervous system (non-CNS) indications.
Represented Broadwing Bio, Inc. in an option and asset sale of Glaucoma program and IP to large pharma.
Represented Notch Therapeutics, Inc. in a research collaboration, licensing agreement to develop iPSC-derived allogeneic cell therapies for hematologic cancers for up to $1 billion, and equity investment by Allogene Therapeutics, Inc.
Represented Arovella Therapeutics in a divestiture of nasal spray business and asset sale of Perth facility.
Represented Arovella Therapeutics in a collaboration with Imugene to combine iNKT CD19 cell therapy with oncolytic vaccine (terms undisclosed).
Advised Arovella Therapeutics on in-license option to IL-12 cytokine technology from University of North Carolina.
Advised Arovella Therapeutics on in-licensing of CAR iNKT CD19 cell therapy program and iNKT cell therapy platform from Imperial College London.
Represented Torque Therapeutics, Inc. in the manufacturing collaboration and co-investment with Thermo Fisher Scientific, Inc. to build cell therapy manufacturing facility for clinical and commercial product supply.
Advised Iveric Bio on the in-licensing of retinitis pigmentosa gene therapy program from University of Florida and University of Pennsylvania.
Public and Private Financings
Advised Apogee Therapeutics, Inc. in the $345 million IPO.
Advised Adagio Therapeutics, Inc. in the $300 million IPO.
Advised Adagio Therapeutics, Inc. in the $336 million series C financing.
Represented Torque Therapeutics, Inc. in the $70 million series B financing.
Advised Tscan Therapeutics, Inc. in connection with the $150 million upsized follow-on public offering.
Advised Repertoire Immune Medicines, Inc. in the $189 million crossover financing.
Advised Voyager Therapeutics, Inc. on the $58 million follow-on public offering.
Represented ADRX, Inc. in the series A financing extension.